Clinical Trials Logo

Neuroendocrine Cancer clinical trials

View clinical trials related to Neuroendocrine Cancer.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06283719 Not yet recruiting - Clinical trials for Small Cell Lung Cancer

Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Advanced Small Cell Lung Cancer

Start date: June 2024
Phase: Phase 1/Phase 2
Study type: Interventional

This is a multicenter, open-label phase I/II study, divided into 2 parts: Part 1 involves a dose-escalation study of ZG006 in which the safety and tolerability of ZG006 in patients with advanced small cell lung cancer or neuroendocrine carcinoma are explored. Upon completion of Part 1, investigators and the sponsor will discuss and determine two recommended phase II doses (RP2D) based on safety, preliminary efficacy, and pharmacokinetic (PK) results for use in Part 2. Part 2 is a phase II dose-expansion study of ZG006, aiming to investigate the efficacy and safety of ZG006 in patients with advanced small cell lung cancer.

NCT ID: NCT02038738 Not yet recruiting - Clinical trials for Neuroendocrine Carcinoma

68Ga-DOTATATE PET Scan Imaging in Patients With Neuroendocrine Tumors

Start date: March 2014
Phase: Phase 1/Phase 2
Study type: Interventional

Neuroendocrine cancer is an unusual disease and often goes undetected by routine imaging. The 68Ga-DOTATATE PET Scan is a novel scanning method that may have improved sensitivity and resolution specifically for neuroendocrine tumors. Patients with neuroendocrine tumors will be imaged with this agent and it will be compared to conventional imaging methods to determine the safety and efficacy of this radiopharmaceutical.